搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
10 小时
The week in pharma: action, reaction and insight – week to January 31
Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...
The Pharma Letter
1 天
Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO
Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...
The Pharma Letter
2 天
Vocabria and Rekambys win EC approval for HIV in adolescents
The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting ...
The Pharma Letter
2 天
FDA nod for Vertex’ non-opioid pain drug Journavx
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
The Pharma Letter
2 天
Rentschler shifts focus away from cell and gene
Rentschler Biopharma is moving away from cell and gene therapy as part of a strategic realignment, opting to focus more on ...
The Pharma Letter
2 天
Novartis ups sales growth and margins in 2024
Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...
The Pharma Letter
2 天
Blackstone builds momentum toward $5 billion biotech fund
Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector ...
The Pharma Letter
2 天
Inhibikase Thera falls as risvodetinib development paused
Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...
The Pharma Letter
2 天
January 2025 EMA-CHMP recommendations
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...
The Pharma Letter
1 天
AbbVie rises on 4th-qtr and full-year 2024 results
US pharma major AbbVie has posted financial results for the fourth quarter and full year ended December 31, 2024, that pleased investors and sending the firm’s shares up 7.8% to $189.19 by mid-morning ...
The Pharma Letter
2 天
New Galderma Phase IIIb data reinforce Relfydess benefits
Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...
The Pharma Letter
2 天
CARGO Thera tanks as it halts FIRCE-1 Phase II study of firi-cel
US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈